Opal achieves the Marketing Authorisation for Fluconazole infusion in the UK, May 2007.
Opal is delighted to have achieved the marketing authorisation for Fluconazole in the UK. Opal intends to market this product very soon and will offer a new intermediate ml size, which will assist physicians, pharmacists and patients in the management of fungal infections.
Yasmin Crawford, MD.

Opal Healthcare Limited moves premises to the South West of the UK.
This is a significant move for Opal developing the business into its next phase...

Click here to read the full story >>

Opal Healthcare and IQA announce collaborative agreement
OXFORD, UK & PRAGUE, CZECH REPUBLIC, October 7th, 2005
Opal Healthcare (Opal) and IQA a.s. today announced a collaborative development, distribution and marketing agreement concerning the injectable antibacterial combination product piperacillin/tazobactam...

Click here to read the full story >>